Glenmark Generics receives Final approval for Rizatriptan Benzoate

January 2, 2013: Glenmark Generics Inc, USA, the United States subsidiary of Glenmark Generics Limited, announced today that the United States Food and Drug Administration (U.S. FDA) has granted final approval for Rizatriptan Benzoate Tablets, its generic version of Merck’s Maxalt® Tablets. . The company has  commenced shipping immediately upon approval.

The approval is for the 5 mg and 10 mg of Rizatriptan.  According to IMS Health for the 12 month period ending Sept 2012, Rizatriptan Benzoate Tablets achieved sales of USD 333 million.Glenmark’s current portfolio consists of 82 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA. The Company remains focused on strategic planning and development and continues its aggressive filing schedule for new ANDA submissions